Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\ - 2Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- 3Bayer sues COVID vaccine makers over mRNA technology
- 4The Best 15 Applications for Efficiency and Association
- 5Want to read more in 2026? Here's how to revive your love of books
- Must-See Attractions in Washington, D.C.
- 75% of US adults may meet criteria for obesity under new definition, study finds
- Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2
- 3 Italian City Cars That Outsmarted Regulations and Rivals
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Best Food Truck Cooking: Decision in favor of Your Number one!
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- 5 Home EV Chargers for Proficient and Solid Charging
- Dominating the Remote Work Way of life: Individual Systems
